Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Neoplasms × Standard of Care × Clear all

Phase

Phase NA 39 Phase 2 6 Phase 3 4 Phase 2/3 3 Phase EARLY_PHASE1 1 Phase 4 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Hematologic Neoplasms 4 Glioma 3 Multiple Myeloma 2 Breast Neoplasms 2 Urologic Neoplasms 1 Urologic Diseases 1 Urogenital Neoplasms 1 Smoking Cessation 1 Sarcoma 1 Osteosarcoma 1 Neoplasms 1 Myelodysplastic Syndromes 1 Monoclonal Gammopathy of Undetermined Significance 1 Medulloblastoma 1 Lung Neoplasms 1 Hypogonadism 1 Hematopoietic and Lymphatic System Neoplasm 1 Heart Failure 1 Gastrointestinal Neoplasms 1 Endometrial Neoplasms 1 Diffuse Intrinsic Pontine Glioma 1 Colonic Neoplasms 1 Colitis 1 Central Nervous System Neoplasms 1 Cardiomyopathies 1 Carcinoma, Non-Small-Cell Lung 1 Anemia, Aplastic 1

Interventions

pembrolizumab 66 Paclitaxel 56 Gemcitabine 50 Carboplatin 50 Cisplatin 39 Docetaxel 36 Bevacizumab 33 Nivolumab 28 Irinotecan 25 Pemetrexed 24 Cyclophosphamide 24 Fluorouracil 23 Capecitabine 22 Erlotinib Hydrochloride 20 venetoclax 19 Cetuximab 19 trametinib 17 Leucovorin 16 Topotecan 15 Afatinib 15 fludarabine 14 Radiotherapy 14 130-nm albumin-bound paclitaxel 14 regorafenib 13 budigalimab 13 Sorafenib 13 Oxaliplatin 13 atezolizumab 12 Doxorubicin 12 Dexamethasone 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01558687 2014-02-04

Cilengitide Imaging Trial in Glioblastoma

Merck KGaA, Darmstadt, Germany

Phase 1 Terminated

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡